JOHNSON & JOHNSON

JNJ - CIK 0000200406

Market cap$573.98 B

Rank#20

SEC filings984

JOHNSON & JOHNSON trades as JNJ and has a market capitalization of $573.98 B, making it the #20 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $94.19B, up 6.0% from the prior year and net income of $26.80B. This page tracks JOHNSON & JOHNSON through 984 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$94.19BFY 2025

Net income (latest FY)$26.80BFY 2025

Operating cash flow (latest FY)$24.53BFY 2025

Total assets (latest FY)$199.21BFY 2025

Gross margin67.9%latest FY

Net margin28.5%latest FY

Financial performance

Over the last 8 fiscal years JOHNSON & JOHNSON's revenue grew from $71.89B to $94.19B, a compound annual growth rate of 3.4%. Net profit margin expanded from 23.0% to 28.5% over the same period - every figure below comes from the company's audited annual filings.

JNJ annual revenueView details

Key statistics

Market cap: $573.98 B
Share price (derived)market cap / shares outstanding: $238.44
P/E ratio (trailing FY): 21.4
EPS (diluted)FY 2025: $11.03
Shares outstandingas of 2026-04-17: 2.41B
Total equityas of 2026-03-29: $81.19B
Return on equity: 33.0%
Long-term debtas of 2026-03-29: $37.53B

Latest filings

Filing	Type	Filed
Institutional holdings	13F-HR	2026-05-13
Insider trade	4	2026-05-04
SCHEDULE 13G	-	2026-05-01
Major company event	8-K	2026-04-28
Insider trade	4	2026-04-27
Insider trade	4	2026-04-27
Insider trade	4	2026-04-27
Insider trade	4	2026-04-27

Browse the full filing history (984 filings)

Recent press releases

2024 Health for Humanity Report2026-05-14
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter2026-05-12
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP2026-05-11
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference2026-05-11
Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission2026-05-07
Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

Similar companies

The largest companies sharing JOHNSON & JOHNSON's SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T JNJ vs LLY

ABBVAbbVie Inc.$399.47 B JNJ vs ABBV

MRKMerck & Co., Inc.$293.16 B JNJ vs MRK

AZNAstraZeneca PLC$286.27 B JNJ vs AZN

NVSNovartis AG$283.13 B JNJ vs NVS

GSK

Frequently asked questions

What is JOHNSON & JOHNSON's market cap?

JOHNSON & JOHNSON (JNJ) has a market capitalization of $573.98 B as of 2026-06-10, ranking #20 among US-listed companies.

How much revenue does JOHNSON & JOHNSON make?

JOHNSON & JOHNSON reported revenue of $94.19B for fiscal year 2025, an increase of 6.0% year over year.

Is JOHNSON & JOHNSON profitable?

Yes. JOHNSON & JOHNSON reported net income of $26.80B in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.